IBM is rewriting its narrative. After years of touting artificial intelligence as the ultimate cost-cutting tool — and slashing entry-level roles accordingly — the technology giant is now tripling its hiring of recent graduates in 2026. The about-face comes as the company simultaneously unveils a 0.7-nanometer chip architecture and sinks billions into a quantum-computing venture, signaling that hardware and human capital are both back at the centre of its strategy.
The latest swing on hiring caught markets by surprise. An internal software system had automated most standard human-resources queries, but complex ethical dilemmas exposed the limits of AI-only recruitment. Industry observers say IBM’s reversal reflects a broader reckoning in tech: eliminating junior positions dries up the talent pipeline needed for sophisticated consulting and engineering work. The company is now actively rebuilding its entry-level bench, a move that investors have started to applaud.
On the technology front, IBM this week presented what it calls the first sub-1-nanometer integrated-circuit process. The 0.7nm design positions the company at the leading edge of semiconductor development, even if commercial production is still at least five years away. The timing is deliberate — the announcement gives IBM a counterweight to the current frenzy around AI-custom chips from rivals such as Nvidia.
Alongside the chip news, IBM formalised its quantum-computing push by establishing a new wafer fabrication subsidiary named Anderon. The company and the U.S. government together contributed the initial $2 billion in capital. Management plans to invest another $9 billion by 2029 under a project code-named Starling, with the aim of building the first fault-tolerant quantum computer. Boston Consulting Group has projected the addressable market for such systems could reach staggering proportions by 2040.
Should investors sell immediately? Or is it worth buying IBM?
The market’s immediate reaction was emphatic. IBM’s stock surged nearly 4% in Wednesday’s session, breaking decisively above its 200-day moving average near $274 — a classic chart-based buy signal that analysts were quick to reinforce. Citigroup raised its price target sharply to $375, while Barclays followed with a $350 forecast. The consensus view now pegs fair value at roughly $306.
Yet the rally is also a catch-up move. IBM’s shares underperformed the broader market last year, weighed down by a debt pile of nearly $58 billion amassed partly through the Confluent acquisition. The consulting division, a traditional earnings anchor, is growing more slowly. The hiring pivot and the chip breakthrough are addressing some of those concerns, but the balance sheet remains a risk.
The real test arrives on July 22, when IBM reports second-quarter earnings. Analysts expect earnings per share of $2.96, an increase of almost 6% year over year. The stock is now flirting with overbought territory on technical measures; the average analyst price target of €258.14 (roughly $282 at current exchange rates) leaves little upside ahead of the print. Investors will be scrutinising whether the quantum and chip investments can start producing tangible revenue and whether the renewed focus on human talent can fuel sustainable growth.
Ad
IBM Stock: Buy or Sell?! New IBM Analysis from July 2 delivers the answer:
The latest IBM figures speak for themselves: Urgent action needed for IBM investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 2.
IBM: Buy or sell? Read more here...
